Literature DB >> 27239458

Reduction of Nodular Growth Pattern of Metastatic Uveal Melanoma after Radioembolization of Hepatic Metastases.

Kevin M Halenda1, Ragini R Kudchadkar2, David H Lawson2, Darren D Kies3, Kristen E Zhelnin4, Alyssa M Krasinskas4, Hans E Grossniklaus5.   

Abstract

AIM: The aim of this study was to report a case of metastatic uveal melanoma in which radioembolized nodular liver metastases decreased in size while infiltrative sinusoidal metastases progressed, leading to jaundice without obstruction of the biliary ducts.
METHODS: The relevant clinical features, imaging, and histopathologic findings of this case are reviewed.
RESULTS: A 61-year-old Caucasian male with a history of uveal melanoma of the left eye status post plaque brachytherapy developed numerous liver metastases. After progression on systemic therapies, he underwent palliative radioembolization. Despite some radiographic improvement in the liver metastases, he developed hyperbilirubinemia without biliary tract obstruction or signs of liver failure. A biopsy of radiographically normal liver demonstrated extensive sinusoidal infiltration with melanoma.
CONCLUSIONS: Distinct angiographic and histopathologic growth patterns of metastatic uveal melanoma differ in their amenability to radioembolization. Sinusoidal infiltration may lead to hyperbilirubinemia in the absence of overt obstruction or liver failure.

Entities:  

Keywords:  Liver metastasis; Micrometastases; Radioembolization; Uveal melanoma

Year:  2015        PMID: 27239458      PMCID: PMC4881272          DOI: 10.1159/000442950

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  28 in total

1.  Improved survival with MEK inhibition in BRAF-mutated melanoma.

Authors:  Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2012-06-04       Impact factor: 91.245

2.  Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging.

Authors:  Shenghui Xue; Hua Yang; Jingjuan Qiao; Fan Pu; Jie Jiang; Kendra Hubbard; Khan Hekmatyar; Jason Langley; Mani Salarian; Robert C Long; Robert G Bryant; Xiaoping Philip Hu; Hans E Grossniklaus; Zhi-Ren Liu; Jenny J Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-13       Impact factor: 11.205

3.  Prognostic factors in uveal melanoma.

Authors:  A D Singh; C L Shields; J A Shields
Journal:  Melanoma Res       Date:  2001-06       Impact factor: 3.599

4.  Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma.

Authors:  Jason J Luke; Hilary Donahue; Mizuki Nishino; Anita Giobbie-Hurder; Meredith Davis; Nancy Bailey; Patrick A Ott; F Stephen Hodi
Journal:  Cancer Immunol Res       Date:  2015-05-05       Impact factor: 11.151

Review 5.  Management of immune-related adverse events and kinetics of response with ipilimumab.

Authors:  Jeffrey S Weber; Katharina C Kähler; Axel Hauschild
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

6.  Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience.

Authors:  Carin F Gonsalves; David J Eschelman; Kevin L Sullivan; P Rani Anne; Laura Doyle; Takami Sato
Journal:  AJR Am J Roentgenol       Date:  2011-02       Impact factor: 3.959

7.  Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment.

Authors:  S Eskelin; S Pyrhönen; P Summanen; M Hahka-Kemppinen; T Kivelä
Journal:  Ophthalmology       Date:  2000-08       Impact factor: 12.079

8.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

Review 9.  Transhepatic therapies for metastatic uveal melanoma.

Authors:  David J Eschelman; Carin F Gonsalves; Takami Sato
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

10.  Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors.

Authors:  A Y Bedikian; S S Legha; G Mavligit; C H Carrasco; S Khorana; C Plager; N Papadopoulos; R S Benjamin
Journal:  Cancer       Date:  1995-11-01       Impact factor: 6.860

View more
  2 in total

1.  Metastatic ocular melanoma to the liver exhibits infiltrative and nodular growth patterns.

Authors:  Hans E Grossniklaus; Qing Zhang; Shuo You; Conni McCarthy; Steffen Heegaard; Sarah E Coupland
Journal:  Hum Pathol       Date:  2016-07-29       Impact factor: 3.466

2.  Radiologic and Histopathologic Correlation of Different Growth Patterns of Metastatic Uveal Melanoma to the Liver.

Authors:  Albert Liao; Pardeep Mittal; David H Lawson; Jenny J Yang; Eszter Szalai; Hans E Grossniklaus
Journal:  Ophthalmology       Date:  2017-11-06       Impact factor: 12.079

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.